Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

In this study, acellular dermal matrix hydrogels significantly improved healing in a rat model of radiation-induced skin injury by promoting angiogenesis and modulating inflammation, suggesting potential as a novel treatment for this common radiotherapy complication.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This paper evaluates the therapeutic response of androgenetic alopecia to topical application of specific compounds using digital drug delivery but reports no new clinical results.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This case report describes severe agranulocytosis and alopecia in a Japanese woman after starting azathioprine, highlighting the potential role of NUDT15 genetic screening in preventing adverse reactions to the drug.

This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.

This study explored the genetic basis of fiber diameter in alpacas, identifying candidate genomic regions including four significant areas on VPA6, VPA9, VPA29, and an unassigned scaffold, using whole genome association analysis and a custom SNP microarray.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

The researchers reported that targeting glycoprotein 130's signaling site in animal models promoted tissue regeneration and reduced osteoarthritis progression through anti-inflammatory and protective effects.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

This study developed a simple method to determine finasteride, indapamide, and tiemonium methylsulfate in pharmaceuticals by using their ability to form silver nanoparticles measurable via spectrophotometry.

In this study, EDA-A2 transgenic mice exhibited multifocal myodegeneration dependent on XEDAR, suggesting a potential role for XEDAR in skeletal muscle homeostasis.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

This study discovered that a specific G to C mutation in the ornithine aminotransferase gene is linked to the retarded hair growth phenotype in mice and may serve as a model for human gyrate atrophy.

This study reports new fluorogenic ceramidase substrates and highlights RBM14C24:1 as an efficient substrate for neutral ceramidase, while RBM15C18:1 is the best probe for measuring ACER1 and ACER2 activities, potentially aiding high-throughput screening for ceramidase inhibitors.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

In this study, ALR was found to enhance both the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells, potentially through specific signaling pathways.